1 May 2010 in Journal of Neurology, Neurosurgery & Psychiatry
CVCatherine Vignal-Clermont
Catherine Vignal-Clermont
+6
The authors report a case of one patient from a family carrying the homoplasmic Leber hereditary optic neuropathy (LHON) G11778A mitochondrial DNA mutation with papilloedema 9 months prior to the acute stage of LHON and still present at the onset of visual loss. During the vision loss, the MRI demonstrated a T2 hyperintensity and an enhancement of the prechiasmal left optic nerve, suggesting the existence of an inflammatory mechanism. A retrospective review of the chart of two others members of the same family, with bilateral optic disc oedema at onset of the vision loss, suggests that the relationship of papilloedema and acute phase of LHON may not be just a coincidence, at least in this family. The visual loss related to LHON could have been triggered in the setting of the chronic papilloedema, associated with the intracranial hypertension.
1 July 2010 in Journal of Clinical Neuroscience
MRMarie-Christine Rousselet
Marie-Christine Rousselet
+1
31 July 2024 in Neurocomputing
27 December 2020 in Clinical Genetics
29 September 2026 in Otolaryngology–Head and Neck Surgery
Objective: Increased MRI use for nonspecific symptoms has led to frequent detection of small or incidental vestibular schwannomas (VS), most of which never require treatment. This study aimed to develop and validate a stepwise model to stratify VS patients using early MRI findings and reduce unnecessary long‐term surveillance. Study Design: Retrospective multicenter cohort study with external validation. Setting: Three tertiary referral centers in France (Strasbourg, Angers) and Switzerland (Frauenfeld). Methods: Patients aged ≥18 years with sporadic VS and ≥3 consecutive MRIs before any intervention were included (2000‐2020). Prior treatment, intralabyrinthine schwannomas, or incomplete imaging led to exclusion. A training cohort (n = 156) and an independent validation cohort (n = 32) were analyzed. Logistic regression and random forest models were used to identify predictors of treatment. A clinically applicable stepwise algorithm integrating baseline tumor volume, annual growth rate, and symptom presence was developed. Results: The optimized model achieved 100% sensitivity in both cohorts, ensuring no patient requiring treatment was missed. Specificity was 74% in the training cohort and 48% in the validation cohort. After 1 follow‐up MRI, surveillance could be safely discontinued in half of the cohorts (respectively 74% and 48% of patients). Larger baseline tumor volume, symptom presence, and higher growth rate were significant predictors of treatment ( P < .05). Conclusion: A stratified, stepwise approach enables safe reduction of long‐term MRI surveillance in approximately half of VS patients, supporting personalized follow‐up and more efficient healthcare use.